Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 196

1.

Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.

Katlama C, Haubrich R, Lalezari J, Lazzarin A, Madruga JV, Molina JM, Schechter M, Peeters M, Picchio G, Vingerhoets J, Woodfall B, De Smedt G; DUET-1, DUET-2 study groups.

AIDS. 2009 Nov 13;23(17):2289-300. doi: 10.1097/QAD.0b013e3283316a5e.

PMID:
19710593
2.

Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.

Schiller DS, Youssef-Bessler M.

Clin Ther. 2009 Apr;31(4):692-704. doi: 10.1016/j.clinthera.2009.04.020. Review.

PMID:
19446143
4.

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.

Lazzarin A, Campbell T, Clotet B, Johnson M, Katlama C, Moll A, Towner W, Trottier B, Peeters M, Vingerhoets J, de Smedt G, Baeten B, Beets G, Sinha R, Woodfall B; DUET-2 study group.

Lancet. 2007 Jul 7;370(9581):39-48.

PMID:
17617271
5.

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

Madruga JV, Cahn P, Grinsztejn B, Haubrich R, Lalezari J, Mills A, Pialoux G, Wilkin T, Peeters M, Vingerhoets J, de Smedt G, Leopold L, Trefiglio R, Woodfall B; DUET-1 study group.

Lancet. 2007 Jul 7;370(9581):29-38.

PMID:
17617270
6.

Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials.

Katlama C, Clotet B, Mills A, Trottier B, Molina JM, Grinsztejn B, Towner W, Haubrich R, Nijs S, Vingerhoets J, Woodfall B, Witek J.

Antivir Ther. 2010;15(7):1045-52. doi: 10.3851/IMP1662.

PMID:
21041921
7.

Etravirine in the treatment of HIV-1: a clinical overview for healthcare professionals.

Yeni P, Mills A, Peeters M, Vingerhoets J, Kakuda TN, De Smedt G, Woodfall B.

Curr HIV Res. 2010 Oct;8(7):564-76. Review.

PMID:
20946097
8.

Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis.

TMC125-C223 Writing Group, Nadler JP, Berger DS, Blick G, Cimoch PJ, Cohen CJ, Greenberg RN, Hicks CB, Hoetelmans RM, Iveson KJ, Jayaweera DS, Mills AM, Peeters MP, Ruane PJ, Shalit P, Schrader SR, Smith SM, Steinhart CR, Thompson M, Vingerhoets JH, Voorspoels E, Ward D, Woodfall B.

AIDS. 2007 Mar 30;21(6):F1-10.

PMID:
17413684
9.

Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227.

Ruxrungtham K, Pedro RJ, Latiff GH, Conradie F, Domingo P, Lupo S, Pumpradit W, Vingerhoets JH, Peeters M, Peeters I, Kakuda TN, De Smedt G, Woodfall B; TMC125-C227 study group.

HIV Med. 2008 Nov;9(10):883-96. doi: 10.1111/j.1468-1293.2008.00644.x. Epub 2008 Sep 14.

10.

Etravirine limits the emergence of darunavir and other protease inhibitor resistance-associated mutations in the DUET trials.

Peeters M, Vingerhoets J, Tambuyzer L, Azijn H, Hill A, De Meyer S, Picchio G.

AIDS. 2010 Mar 27;24(6):921-4. doi: 10.1097/QAD.0b013e328336ac2a.

PMID:
20160633
11.

Safety of etravirine in HIV-1/hepatitis B and/or C virus co-infected patients: pooled 96 week results from the Phase III DUET trials.

Clotet B, Clumeck N, Katlama C, Nijs S, Witek J.

J Antimicrob Chemother. 2010 Nov;65(11):2450-4. doi: 10.1093/jac/dkq332. Epub 2010 Aug 27.

PMID:
20801782
12.

Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection.

Montaner J, Yeni P, Clumeck NN, Fätkenheuer G, Gatell J, Hay P, Seminari E, Peeters MP, Schöller-Gyüre M, Simonts M, Woodfall B; TMC125-C203 Study Group.

Clin Infect Dis. 2008 Oct 1;47(7):969-78. doi: 10.1086/591705.

PMID:
18764771
13.

High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.

Yazdanpanah Y, Fagard C, Descamps D, Taburet AM, Colin C, Roquebert B, Katlama C, Pialoux G, Jacomet C, Piketty C, Bollens D, Molina JM, Chêne G; ANRS 139 TRIO Trial Group.

Clin Infect Dis. 2009 Nov 1;49(9):1441-9. doi: 10.1086/630210.

PMID:
19814627
14.

Impact of the background regimen on virologic response to etravirine: pooled 48-week analysis of DUET-1 and -2.

Trottier B, Di Perri G, Madruga JV, Peeters M, Vingerhoets J, Picchio G, Woodfall BJ.

HIV Clin Trials. 2010 Jul-Aug;11(4):175-85. doi: 10.1310/hct1104-175.

PMID:
20974573
15.

Etravirine: R165335, TMC 125, TMC-125, TMC125.

[No authors listed]

Drugs R D. 2006;7(6):367-73. Review.

PMID:
17073519
16.

Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients.

Kakuda TN, Wade JR, Snoeck E, Vis P, Schöller-Gyüre M, Peeters MP, Corbett C, Nijs S, Vingerhoets J, Leopold L, De Smedt G, Woodfall BJ, Hoetelmans RM.

Clin Pharmacol Ther. 2010 Nov;88(5):695-703. doi: 10.1038/clpt.2010.181. Epub 2010 Sep 29.

PMID:
20881958
17.

[Darunavir in patients with advanced HIV and multiresistance. The POWER, DUET and BENCHMRK studies].

Arazo Garcés P, Omiste Sanvicente T.

Enferm Infecc Microbiol Clin. 2008 Oct;26 Suppl 10:23-31. Review. Spanish.

PMID:
19195456
18.

Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirine-containing regimen in the DUET-1 and DUET-2 clinical studies.

Tambuyzer L, Vingerhoets J, Azijn H, Daems B, Nijs S, de Béthune MP, Picchio G.

AIDS Res Hum Retroviruses. 2010 Nov;26(11):1197-205. doi: 10.1089/aid.2009.0302. Epub 2010 Sep 20.

PMID:
20854144
19.

Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.

Boffito M, Winston A, Jackson A, Fletcher C, Pozniak A, Nelson M, Moyle G, Tolowinska I, Hoetelmans R, Miralles D, Gazzard B.

AIDS. 2007 Jul 11;21(11):1449-55.

PMID:
17589191
20.

[Etravirine in highly treatment-experienced patients].

Palter DP, Corbera EF, Tiraboschi JM.

Enferm Infecc Microbiol Clin. 2009 Dec;27 Suppl 2:6-11. doi: 10.1016/S0213-005X(09)73213-6. Review. Spanish.

PMID:
20116622

Supplemental Content

Support Center